Guggenheim Capital LLC Dyne Therapeutics, Inc. Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 26,018 shares of DYN stock, worth $314,297. This represents 0.01% of its overall portfolio holdings.
Number of Shares
26,018
Previous 31,857
18.33%
Holding current value
$314,297
Previous $1.14 Million
46.5%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$96.9 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$89.2 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$89.1 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$81 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$77.1 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $625M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...